Literature DB >> 25514802

ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice.

Vittoria Martin1, Barbara Bernasconi, Elisabetta Merlo, Piera Balzarini, William Vermi, Alice Riva, Anna Maria Chiaravalli, Milo Frattini, Nora Sahnane, Fabio Facchetti, Luca Mazzucchelli, Fausto Sessa, Maria Grazia Tibiletti.   

Abstract

INTRODUCTION: Anaplastic lymphoma kinase (ALK) gene rearrangement characterizes a subgroup of patients with lung adenocarcinoma who may benefit from ALK inhibitors. Fluorescence in situ hybridization (FISH) with a break-apart/split-signal strategy is the gold standard to investigate ALK. The cutoff to define ALK positivity has been settled at 15% or greater. A subset of patients has ALK borderline status, showing 15% ± 5% positive cells. Several aspects, both biological and technical, might influence signals evaluation, making FISH interpretation a challenging task. To improve ALK evaluation, we classified the different FISH patterns on the basis of the type of the split signals, namely short, long, far away, and deleted.
METHODS: We investigated ALK gene status by FISH in 244 lung adenocarcinomas and in a series of ALK negative cell lines samples, collected in three Institutions.
RESULTS: ALK positive profile was found in 12% of patients; long, deleted, and far-away splits were the primary patterns observed. ALK borderline profile characterized 10% of samples; long and deleted splits were significantly more frequent in those borderline finally classified as ALK positive, whereas short split were mostly detected in those borderline patients finally classified as ALK negative (p = 3.4 × 10). In the ALK negative control series, short split was the predominant pattern. Concordance was observed among different operators and probes for both samples and controls.
CONCLUSIONS: Difficulties in ALK FISH signal interpretation might be bypassed using this detailed scoring system, which is highly reproducible, helps clarify borderline samples (according to split type), and provides experimental evidence that 15% is a reasonable cutoff to overcome the assay-dependent background noise.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25514802     DOI: 10.1097/JTO.0000000000000444

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  15 in total

1.  CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer.

Authors:  Giorgio Maria Agazzi; Marco Ravanelli; Elisa Roca; Daniela Medicina; Piera Balzarini; Carlotta Pessina; William Vermi; Alfredo Berruti; Roberto Maroldi; Davide Farina
Journal:  Radiol Med       Date:  2021-01-29       Impact factor: 3.469

2.  Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer.

Authors:  Liang Zeng; Yizhi Li; Qinqin Xu; Nong Yang; Zhenxing Wang; Wenjuan Jiang; Analyn Lizaso; Xinru Mao; Yongchang Zhang
Journal:  Onco Targets Ther       Date:  2020-07-22       Impact factor: 4.147

Review 3.  ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

4.  Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non-Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases.

Authors:  Anna Scattone; Annamaria Catino; Laura Schirosi; Lucia Caldarola; Stefania Tommasi; Rosanna Lacalamita; Elisabetta Sara Montagna; Domenico Galetta; Gabriella Serio; Francesco Alfredo Zito; Anita Mangia
Journal:  Transl Oncol       Date:  2018-12-04       Impact factor: 4.243

Review 5.  Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects.

Authors:  Zhenya Tang; Lu Wang; Guilin Tang; L Jeffrey Medeiros
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

Review 6.  Identifying patients with NTRK fusion cancer.

Authors:  J P Solomon; R Benayed; J F Hechtman; M Ladanyi
Journal:  Ann Oncol       Date:  2019-11-01       Impact factor: 32.976

7.  Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases.

Authors:  Yongfeng Yu; Zhengping Ding; Lei Zhu; Haohua Teng; Shun Lu
Journal:  Springerplus       Date:  2016-06-27

8.  Novel method for rapid fluorescence in-situ hybridization of ALK rearrangement using non-contact alternating current electric field mixing.

Authors:  Satoshi Fujishima; Kazuhiro Imai; Ryuta Nakamura; Hiroshi Nanjo; Yoshitaro Saito; Hajime Saito; Kaori Terata; Yusuke Sato; Satoru Motoyama; Yoichi Akagami; Yoshihiro Minamiya
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

9.  Clinical evaluation of the effectiveness of fusion-induced asymmetric transcription assay-based reverse transcription droplet digital PCR for ALK detection in formalin-fixed paraffin-embedded samples from lung cancer.

Authors:  Yuanyuan Liu; Shafei Wu; Xiaohua Shi; Linping Lu; Lingxiang Zhu; Yong Guo; Li Zhang; Xuan Zeng
Journal:  Thorac Cancer       Date:  2020-06-16       Impact factor: 3.500

10.  ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?

Authors:  Florian Cabillic; Paul Hofman; Marius Ilie; Nir Peled; Maximilian Hochmair; Manfred Dietel; Maximilian Von Laffert; John R Gosney; Fernando Lopez-Rios; Gilles Erb; Uwe Schalles; Fabrice Barlesi
Journal:  ESMO Open       Date:  2018-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.